Search

Twenty-nine European Union/European Economic Area (EU/EEA) countries reported cases of pathogens with antimicrobial resistance (AMR) to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 2021, based on data for invasive bacterial isolates (i.e. retrieved from blood or cerebrospinal fluid).

This report describes and summarises the national results of the external quality assessment (EQA) of laboratory performance for those laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2021.

The results presented in this report are based on antimicrobial resistance (AMR) data from invasive isolates reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) by 29 European Union (EU) and European Economic Area (EEA) countries in 2021 (data referring to 2020), and on trend analyses of data reported by the continuously participating countries for the period 2016 to 2020. 

This report is based on data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the period 2015 to 2019, retrieved from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI) on 10 September 2020.

Over the last four years (2011 to 2014), the percentages of Klebsiella pneumonia e resistant to fluoroquinolones, third-generation cephalosporins and aminoglycosides, as well as combined resistance to all three antimicrobial groups, has increased significantly at the EU/EEA level.

This report aims to provide updated estimates of the burden of infections with selected bacterium–antibiotic resistance combinations in the EU/EEA in 2016-2020 and assess how this burden has changed from previous estimates.